Why Psychiatry Is Finally Breaking Free From Dopamine

In this episode of Power to the Patients, host Brandon Li sits down with Ken Kramer, PhD, Vice President and Head of Neuropsychiatry Medical Affairs at Bristol Myers Squibb, to explore why psychiatry has lagged behind other therapeutic areas and what’s finally changing. Kramer explains how decades of reliance on dopamine-based antipsychotics shaped treatment, and why new mechanisms like muscarinic agonism are opening the door to safer, more effective options for patients with schizophrenia.